Cimzia vs Omvoh for Crohn's Disease: Which Is Better?

Cimzia and Omvoh represent two very different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Omvoh (mirikizumab) is a newer IL-23 p19-selective biologic that gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these drugs weigh established anti-TNF mechanism against a newer IL-23 class. This guide walks through the cimzia vs omvoh crohn's comparison.

Anti-TNF vs IL-23 p19 Mechanism

Cimzia binds TNF-alpha, a cytokine that drives inflammation throughout the body and in the gut. Omvoh binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 is a central driver of Th17-mediated inflammation in Crohn's. The certolizumab vs mirikizumab distinction shapes both speed of onset and the long-term safety profile. Cimzia's broader TNF blockade produces rapid systemic anti-inflammatory effects. Omvoh's selective IL-23 inhibition produces strong efficacy with a cleaner infection profile.

Efficacy in Crohn's

Cimzia's Crohn's efficacy rests on PRECISE-1 and PRECISE-2, which showed significant clinical response and remission benefits over placebo. Omvoh's Crohn's efficacy rests on VIVID-1, a three-arm trial comparing mirikizumab with placebo and with ustekinumab (Stelara). VIVID-1 showed mirikizumab superior to placebo on co-primary endpoints of clinical remission and endoscopic response, with a key secondary endpoint establishing non-inferiority to Stelara. No head-to-head trial has directly compared Cimzia with Omvoh in Crohn's. Indirect comparisons suggest Omvoh offers comparable clinical remission in biologic-naive patients and potentially better endoscopic outcomes, while Cimzia offers earlier onset.

Onset of Action

Cimzia produces meaningful Crohn's response by week 6 based on PRECISE. Omvoh's Crohn's onset produces meaningful response by week 12 based on VIVID-1. For Crohn's patients with severe, active symptoms who need rapid control, Cimzia's faster onset is often preferred. For patients in less acute states or those weighing long-term safety, Omvoh's response trajectory is generally acceptable.

Safety and Infection Risk

Cimzia carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Omvoh's Crohn's safety data from VIVID-1 has been favorable, consistent with IL-23 p19 class effects. Long-term data for IL-23 p19 biologics consistently shows lower rates of serious systemic infection than anti-TNFs. For cimzia vs omvoh side effects in patients with infection concerns, cancer history, or comorbidities, Omvoh's narrower mechanism often looks more favorable. Both drugs require TB and hepatitis B screening before starting.

Administration and Dosing

Cimzia for Crohn's uses 400 mg SC at weeks 0, 2, and 4 for induction, then 400 mg every 4 weeks for maintenance, per UCB's prescribing information. Cimzia is all-SC throughout. Omvoh for Crohn's uses IV induction at 900 mg every 4 weeks for three doses (weeks 0, 4, and 8), followed by subcutaneous maintenance at 300 mg every 4 weeks (administered as two 150 mg injections), per Lilly's prescribing information. For Crohn's patients comparing administration, Cimzia is fully SC, while Omvoh requires IV induction before transitioning to SC maintenance. Both drugs maintain on every-4-week SC cadence.

Fistulizing Crohn's

For fistulizing Crohn's complications, anti-TNFs including Cimzia have historically had the strongest trial data. Omvoh's fistulizing data from VIVID-1 is emerging but is not as extensive as anti-TNF class data. For Crohn's patients with significant perianal disease, the choice between Cimzia and Omvoh often includes consideration of this factor.

Pregnancy Considerations

Cimzia's lack of an Fc region minimizes active placental transfer during pregnancy, resulting in very low infant drug levels at birth. Omvoh undergoes active placental transfer via FcRn like other IgG biologics. For Crohn's patients who are pregnant or planning pregnancy and need to maintain biologic therapy through delivery, Cimzia's pregnancy profile is often preferred.

Anti-TNF Experienced Patients

For patients who have failed or lost response to a prior anti-TNF, a mechanism switch to Omvoh is supported by VIVID-1 data, which included biologic-experienced patients. Cycling within the anti-TNF class typically delivers lower response rates than changing mechanism classes. For Crohn's patients with prior anti-TNF exposure, Omvoh often has better expected response.

Choosing With Your GI

For a Crohn's patient deciding between Cimzia and Omvoh, Cimzia tends to win on faster onset, fully SC administration throughout, pregnancy considerations, fistulizing disease outcomes, and a longer track record in Crohn's. Omvoh tends to win on long-term safety, head-to-head comparator data against Stelara (VIVID-1), and performance in anti-TNF experienced patients. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.